Key Facts
• July 30, 2025: Astellas Pharma announced Q1 operating profit rose 86.8% YoY to ¥94.6 billion.
• Full-year operating profit forecast for FY2026 remains at ¥160 billion, a 3.8x increase YoY.
• Q1 growth driven by strategic product sales expansion and cost optimization.
• Revenue for Q1 reached ¥505.8 billion, a 6.9% increase YoY.
• Net profit for Q1 was ¥68.4 billion, up 82% YoY.
• Full-year revenue forecast for FY2026 is ¥1.93 trillion, a 0.9% increase YoY.
• Dividend forecast for FY2026 remains unchanged at ¥78 per share.
Summary
Astellas Pharma reported an 86.8% year-on-year increase in operating profit for the first quarter of FY2025, reaching ¥94.6 billion. This growth was attributed to the expansion of strategic product sales and cost optimization efforts. The company maintained its full-year forecast for FY2026, projecting an operating profit of ¥160 billion, a 3.8x increase compared to the previous year. Revenue for the quarter rose 6.9% year-on-year to ¥505.8 billion, while net profit increased by 82% to ¥68.4 billion. The full-year revenue forecast remains at ¥1.93 trillion, with no changes to the dividend forecast of ¥78 per share. These results highlight Astellas’ strong performance and strategic focus on key growth areas.
